Meet the AdvisorsAntibody-Drug Conjugates


Day 1 | Day 2 | Download Stream Brochure 

Thursday, May 12

12:00 pm Registration



1:30 Chairperson’s Opening Remarks

Pam TrailPamela A. Trail, Ph.D., Vice President, Oncology Program Direction, Regeneron Pharmaceuticals, Inc.


1:40 Understanding the Influence of Conjugation Site on the Stability and Biological Activity of Antibody-Drug Conjugates

Keyang XuKeyang Xu, Ph.D., Scientist, BioAnalytical Sciences, Genentech, Inc.

Site-specific conjugation generates homogeneous ADCs. Drug deconjugation of the ADC is studied both in vitro and in vivo using novel analytical approaches to evaluate the impact of conjugation site on the ADC’s stability and biological activity.


2:10 Strategies to Control Stoichiometry and Site of Cysteine-Directed Antibody Drug Conjugation

Nazzareno DimasiNazzareno Dimasi, Ph.D., Senior Scientist, Antibody Discovery & Engineering, MedImmune

Classical ADC platforms often rely on the random modification of sulfhydryl, amine, or carboxyl groups and thus have unpredictable stability, solubility, and product quality. Here we discuss our effort to engineer cysteine into antibody Fc-region to address the challenges pertaining to classical ADCs and provide the data of our engineered antibodies with predefined sites and stoichiometries to improve conjugation efficiency and product homogeneity.


2:40 Sponsored Presentations (Opportunities Available)

3:10 Refreshment Break in the Exhibit Hall & Poster Viewing


4:00 Problem Solving Breakout Sessions 

Concurrent Problem Solving Breakouts are interactive sessions hosted by a moderator to discuss a topic in depth. They are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in. 

TABLE 12: Better Understanding the Stability of Antibody-Drug Conjugates 

Moderator: Keyang Xu, Ph.D., Scientist, BioAnalytical Sciences, Genentech, Inc. 

• How can we effectively assess the ADC stability? What experiments should be included and what bioanalytical methods should be applied?
• Which factors may impact the ADC stability?
• What mechanisms may be involved in the drug deconjugation from the ADC?
• Is there any correlation between in vitro and in vivo stability?

TABLE 13: Antibody-Drug Conjugates: Targeted Drug Delivery for Cancer 

Moderator: Django Sussman, Ph.D., Principal Scientist, Experimental Therapeutics, Seattle Genetics, Inc. 


TABLE 14: Use of Unnatural Amino Acids for Multivalent Antibody Platforms 

Moderator: Vaughn V. Smider, M.D., Ph.D., Founder, Fabrus LLC; Assistant Professor, Molecular Biology, The Scripps Research Institute 


TABLE 15: Directing Therapeutic Antibodies by Light 

Moderator: Colin Self, B.Sc., M.B., B.Chir., Ph.D., D.Sc., FRCPath, FRSC, CEO, BioTransformations Ltd. and The Medical School, Newcastle upon Tyne 

• Does great specificity of pharmaceuticals really matter?
• Where are the specificity challenges and limits of biopharmaceuticals? 
• What could be achieved with real 'exquisite' specificity?
• What are the opportunities for light-directed enhancement in achieving this?

5:00 Close of Day

Day 1 | Day 2 | Download Stream Brochure